Arcutis Biotherapeutics, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Arcutis Biotherapeutics is a biopharmaceutical company that develops and markets treatments for immune-mediated dermatological diseases, including topical and other therapies for conditions such as plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Matsuda MasaruSee Remarks | Sell | $250K | 9,989at $25.03 | Sep 8, 2026 |
| Curran TerrieDirector | Sell | $677K | 27,052at $25.03 | Aug 27, 2026 |
| Curran TerrieDirector | Sell | $279K | 11,148at $25.03 | Aug 27, 2026 |
| Burnett PatrickSee Remarks | Sell | $175K | 6,700at $26.08 | Aug 12, 2026 |
| Burnett PatrickSee Remarks | Sell | $220K | 8,300at $26.52 | Aug 11, 2026 |
| Watanabe ToddSee Remarks | Sell | $114K | 4,375at $26.12 | Aug 3, 2026 |
| Burnett PatrickSee Remarks | Sell | $25K | 955at $26.12 | Aug 3, 2026 |
| Matsuda MasaruSee Remarks | Sell | $32K | 1,230at $26.12 | Aug 3, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable ARQT activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.